

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934**

**For the Month of: August 2018**

**Commission File Number: 001-37847**

**MOTIF BIO PLC**

(Exact name of registrant as specified in its charter)

**125 Park Avenue**

**25<sup>th</sup> Floor**

**New York, New York 10017**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**MOTIF BIO PLC  
FORM 6-K**

**REGULATORY NEWS SERVICE ANNOUNCEMENT**

On August 21, 2018, Motif Bio plc (the "Company") issued a regulatory news service announcement, a copy of which is attached as Exhibit 99.1 to this report on Form 6-K, announcing the sale of ordinary shares by Amphion Innovations, plc ("Amphion"), a substantial shareholder in the Company, relating to its sale of shares in Motif Bio to an institutional investor. Amphion now holds 8.51% of the issued share capital of Motif Bio.

The information contained in this report on Form 6-K, including Exhibit 99.1 attached hereto, is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File Nos. 333-222614 and 333-222042), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**Exhibits**

Exhibit 99.1 [Regulatory news service announcement issued by Motif Bio plc, dated August 21, 2018, entitled "Motif Bio notes statement from Amphion Innovations."](#)

2

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MOTIF BIO PLC

By: /s/ Graham Lumsden  
Name: Graham Lumsden  
Title: Chief Executive Officer

Date: August 21, 2018

3



21 August 2018

**Motif Bio plc**  
 (“Motif Bio” or the “Company”)

**Motif Bio notes statement from Amphion Innovations**

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement made today via RNS by Amphion Innovations plc (“Amphion”), a substantial shareholder in the Company, relating to its sale of shares in Motif Bio to an institutional investor. Amphion now holds 8.51% of the issued share capital of Motif Bio. The full TR-1 disclosure is set out below.

For further information please contact:

|   |  |
|---|--|
| <b>Motif Bio plc</b><br>Graham Lumsden (Chief Executive Officer)                                    | info@motifbio.com  |
| <b>Peel Hunt LLP (NOMAD &amp; BROKER)</b><br>Dr Christopher Golden<br>Oliver Jackson                | + 44 (0)20 7418 8900   |
| <b>Northland Capital Partners Limited (BROKER)</b><br>David Hignell/Vadim Alexandre/Rob Rees        | +44 (0)20 3861 6625  |
| <b>Walbrook PR Ltd. (UK FINANCIAL PR &amp; IR)</b><br>Paul McManus/Helen Cresswell/Lianne Cawthorne | +44 (0)20 7933 8780<br>motifbio@walbrookpr.com   |
| <b>MC Services AG (EUROPEAN IR)</b><br>Raimund Gabriel  | +49 (0) 89 210 2280<br>raimund.gabriel@mc-services.eu  |
| <b>Solebury Trout (U.S. IR)</b><br>Meggie Purcell   | + 1 (646) 378-2963<br>mpurcell@troutgroup.com  |
| <b>Russo Partners (U.S. PR)</b><br>David Schull<br>Travis Kruse, Ph.D.                              | +1 (858) 717-2310 or +1 (212) 845 4272<br>david.schull@russopartnersllc.com<br>travis.kruse@russopartnersllc.com |

**TR-1: Standard form for notification of major holdings**

**NOTIFICATION OF MAJOR HOLDINGS** (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)(i)

**1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached(ii):** Motif Bio plc

**1b. Please indicate if the issuer is a non-UK issuer** (please mark with an “X” if appropriate)

Non-UK issuer 0

1

**2. Reason for the notification** (please mark the appropriate box or boxes with an “X”)

|   |   |
|---|---|
| An acquisition or disposal of voting rights         | X |
| An acquisition or disposal of financial instruments | 0 |
| An event changing the breakdown of voting rights    | 0 |
| Other (please specify)(iii):                        | 0 |

**3. Details of person subject to the notification obligation(iv)**

Name Amphion Innovations plc

City and country of registered office (if applicable)

**4. Full name of shareholder(s)** (if different from 3.)(v)

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached(vi): August 20 2018

6. Date on which issuer notified (DD/MM/YYYY): August 20 2018

7. Total positions of person(s) subject to the notification obligation

|   | % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuer(vii) |
|---|---|---|--------------------------------|--|
| Resulting situation on the date on which threshold was crossed or reached | 8.51%   |   |                                | 296,660,243                                  |
| Position of previous notification (if applicable)                         | 9.53%   |   |                                |  |

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached(viii)

A: Voting rights attached to shares

| Class/type of shares<br>ISIN code (if possible) | Number of voting rights(ix)                      |   | % of voting rights                               |   |
|---|--|---|--|---|
|   | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
| GB008BVVT4H71                                   | 25,254,611                                       |   | 8.51%  |   |
| <b>SUBTOTAL 8. A</b>                            | 25,254,611                                       |   | 8.51%  |   |

2

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

| Type of financial instrument | Expiration date(x) | Exercise/ Conversion Period(xi) | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights |
|------------------------------|--------------------|---------------------------------|--|--------------------|
| <b>SUBTOTAL 8. B 1</b>       |                    |                                 |  |                    |

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

| Type of financial instrument | Expiration date(x) | Exercise/ Conversion Period (xi) | Physical or cash settlement(xii) | Number of voting rights | % of voting rights |
|------------------------------|--------------------|----------------------------------|----------------------------------|-------------------------|--------------------|
| <b>SUBTOTAL 8.B.2</b>        |                    |                                  |                                  |                         |                    |

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer(xiii)

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(xiv) (please add additional rows as necessary)

| Name(xv) | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
|----------|--|--|---|
|          |  |  |   |

3

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

**11. Additional information**(xvi)

**Place of completion**

**Date of completion** August 20 2018

**Annex: Notification of major holdings** (to be filed with the FCA only)

**A: Identity of the person subject to the notification obligation**

Full name (including legal form for legal entities)

Contact address (registered office for legal entities)

E-Mail

Phone number / Fax number

Other useful information

(at least legal representative for legal persons)

**B: Identity of the notifier, if applicable**

Full name

Amphion Innovations plc

Contact address

125 Park Avenue, 25<sup>th</sup> Floor  
New York, NY 10017  
USA

E-Mail

cmorgan@amphionplc.com

Phone number / Fax number

+1 (212) 210 6282

Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)

**C: Additional information**

Please send the completed form together with this annex to the FCA at the following email address: Majorshareholdings@fca.org.uk. Please send in Microsoft Word format if possible.

**Notes**

*(i) Please note that national forms may vary due to specific national legislation (Article 3(1a) of Directive 2004/109/EC) as for instance the applicable thresholds or information regarding capital holdings.*

*(ii) Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.*

*(iii) Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.*

*(iv) This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h)/ Article 10 (b) to (h) of Directive 2004/109/EC; (c) all parties to the agreement referred to in Article 10 (a) of Directive 2004/109/EC (DTR5.2.1 (a)) or (d) the holder of financial instruments referred to in Article 13(1) of Directive 2004/109/EC (DTR5.3.1).*

*As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.*

*In relation to the transactions referred to in points (b) to (h) of Article 10 of Directive 2004/109/EC (DTR5.2.1 (b) to (h)), the following list is provided as indication of the persons who should be mentioned:*

- in the circumstances foreseen in letter (b) of Article 10 of that Directive (DTR5.2.1 (b)), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;*

· in the circumstances foreseen in letter (c) of Article 10 of that Directive (DTR5.2.1 (c)), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

· in the circumstances foreseen in letter (d) of Article 10 of that Directive (DTR5.2.1 (d)), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

· in the circumstances foreseen in letter (e) of Article 10 of that Directive (DTR5.2.1 (e)), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9 (DTR 5.1), under letters (a) to (d) of Article 10 of that Directive (DTR5.2.1 (a) to (d)) or under a combination of any of those situations, the controlled undertaking;

· in the circumstances foreseen in letter (f) of Article 10 of that Directive (DTR5.2.1 (f)), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

· in the circumstances foreseen in letter (g) of Article 10 of that Directive (DTR5.2.1 (g)), the natural person or legal entity that controls the voting rights;

· in the circumstances foreseen in letter (h) of Article 10 of that Directive (DTR5.2.1 (h)), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

(v) Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC (DTR5.2.1 (b) to (h)). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive (DTR5.2) unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

(vi) The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

(vii) The total number of voting rights shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

(viii) If the holding has fallen below the lowest applicable threshold in accordance with national law, please note that it might not be necessary in accordance with national law to disclose the extent of the holding, only that the new holding is below that threshold.

6

---

(ix) In case of combined holdings of shares with voting rights attached “direct holding” and voting rights “indirect holding”, please split the voting rights number and percentage into the direct and indirect columns — if there is no combined holdings, please leave the relevant box blank.

(x) Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

(xi) If the financial instrument has such a period — please specify this period — for example once every 3 months starting from [date].

(xii) In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (Article 13(1a) of Directive 2004/109/EC) (DTR 5.3.3.A).

(xiii) If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

(xiv) The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only thus the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain leaving a row free between different chains (e.g.: A, B, C, free row, A, B, D, free row, A, E, F etc.).

(xv) The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

(xvi) Example: Correction of a previous notification.

7

---